AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37756299 — intervention group
Group type: COMPARATOR
Intervention: Influenza infection
Number of subjects: 35806
Study 37756299 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 80 years vs. age 50 years
Number of subjects: 35806
Study 37756299 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild-type/delta variant infection vs. influenza infection
Number of subjects: 35806
Study 37756299 — intervention group
Group type: EXPERIMENTAL
Intervention: Omicron variant infection vs. influenza infection
Number of subjects: 35806
Study 37756321 — intervention group
Group type: EXPERIMENTAL
Intervention: e-registration tracking system and mHealth counseling
Number of subjects: 536
Study 37756321 — intervention group
Group type: COMPARATOR
Intervention: Control group (no e-registration and mHealth counseling)
Number of subjects: 536
Study 37756532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib maintenance (I-M) 560 mg daily for up to 4 years
Number of subjects: 36
Study 37756532 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibrutinib maintenance (I-M)
Number of subjects: 36
Study 37757502 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialized oral nutritional supplement (S-ONS)
Number of subjects: 622
Study 37757502 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 622
Study 37757520 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 800
Study 37757520 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 800
Study 37757520 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor or Clopidogrel
Number of subjects: 800
Study 37757587 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients (≥70 years old)
Number of subjects: 157
Study 37757587 — intervention group
Group type: COMPARATOR
Intervention: Younger patients
Number of subjects: 157
Study 37757844 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered counseling with participant-selected adherence supporter
Number of subjects: 200
Study 37757844 — intervention group
Group type: COMPARATOR
Intervention: Standard counseling (control)
Number of subjects: 200
Study 37757868 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported gestational age categories
Number of subjects: 4684
Study 37757868 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported gestational age sensitivity
Number of subjects: 4684
Study 37757868 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported gestational age specificity
Number of subjects: 4684
Study 37757868 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analyses for various parent and socioeconomic factors
Number of subjects: 4684
Study 37757868 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with lower sensitivity and/or specificity
Number of subjects: 4684
Study 37757873 — intervention group
Group type: EXPERIMENTAL
Intervention: Capture-recapture approach
Number of subjects: 0
Study 37757873 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian model
Number of subjects: 0
Study 37757880 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilization approach
Number of subjects: 396
Study 37757880 — intervention group
Group type: COMPARATOR
Intervention: House-to-house approach
Number of subjects: 396
Study 37757880 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilization approach in multiple-visit villages
Number of subjects: 396
Study 37757880 — intervention group
Group type: COMPARATOR
Intervention: House-to-house approach in multiple-visit villages
Number of subjects: 396
Study 37757966 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycated serum proteins
Number of subjects: 334
Study 37757966 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin
Number of subjects: 334
Study 37757966 — intervention group
Group type: EXPERIMENTAL
Intervention: GA/HbA1c ratio
Number of subjects: 334
Study 37757966 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein
Number of subjects: 334
Study 37757966 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 334
Study 37758507 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluobeam® LX
Number of subjects: 535
Study 37758507 — intervention group
Group type: COMPARATOR
Intervention: Control (no use of Fluobeam® LX)
Number of subjects: 535
Study 37758574 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab maintenance therapy (intravenous nivolumab 8 × 240 mg every 2 weeks, followed by 480 mg every 4 weeks)
Number of subjects: 49
Study 37758574 — intervention group
Group type: COMPARATOR
Intervention: Tyrosine kinase inhibitor (TKI) maintenance therapy (sunitinib 50 mg or pazopanib 800 mg once daily)
Number of subjects: 49
Study 37758623 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine
Number of subjects: 210
Study 37758623 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural bupivacaine with morphine
Number of subjects: 210
Study 37758649 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based adherence support intervention for daily oral PrEP
Number of subjects: 603
Study 37758649 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based PrEP delivery platform and behavioural intervention
Number of subjects: 603
Study 37758649 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable PrEP
Number of subjects: 603
Study 37758649 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions integrating long-term planning skills and social support
Number of subjects: 603
Study 37758676 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Neuroscience Education (PNE) combined with conventional treatment, 9 sessions (1 session/week for 9 weeks), each lasting 30-40 min
Number of subjects: 80
Study 37758676 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (pharmacological treatment)
Number of subjects: 80
Study 37758678 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires assessing anxiety, depression, post-traumatic stress symptoms, health-related quality of life and physical symptoms at 3, 6 and/or 12 months after ICU discharge
Number of subjects: 0
Study 37758711 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy
Number of subjects: 22
Study 37758711 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonal evolution analysis of longitudinally collected tumour samples
Number of subjects: 22
Study 37758711 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment immunogenicity analysis
Number of subjects: 22
Study 37758864 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential platelet/endothelial activation
Number of subjects: 0
Study 37758864 — intervention group
Group type: COMPARATOR
Intervention: Culture positive sepsis
Number of subjects: 0
Study 37758864 — intervention group
Group type: COMPARATOR
Intervention: Culture negative sepsis with 5 days of antibiotics
Number of subjects: 0
Study 37758864 — intervention group
Group type: COMPARATOR
Intervention: Non sepsis
Number of subjects: 0
Study 37758967 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist evaluation and monitoring based on the implementation of a recently published checklist including evaluation of appropriateness of DOAC, need for affordability assistance, three pharmacist-initiated telephone consultations, access to a DOAC hotline, documented hand-off to continuity provider, and monitoring of follow-up laboratory tests.
Number of subjects: 561
Study 37758967 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist evaluation and monitoring based on the implementation of a recently published checklist.
Number of subjects: 561
Study 37758967 — intervention group
Group type: EXPERIMENTAL
Intervention: Coupons and assistance to increase the affordability of DOACs.
Number of subjects: 561
Study 37758967 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care without pharmacist intervention).
Number of subjects: 561
Study 37759037 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-session intervention including a visuospatial task delivered by trained maternity clinicians.
Number of subjects: 146
Study 37759037 — intervention group
Group type: COMPARATOR
Intervention: Attention-placebo control group
Number of subjects: 146
Study 37759099 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic therapy achieving PASI90
Number of subjects: 687
Study 37759148 — intervention group
Group type: EXPERIMENTAL
Intervention: INOSEL program (Integrative Nursing and Omaha System)
Number of subjects: 69
Study 37759148 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 69
Study 37759174 — intervention group
Group type: EXPERIMENTAL
Intervention: PaGES Index (Participant-Generated Experience and Satisfaction Index)
Number of subjects: 68
Study 37759174 — intervention group
Group type: EXPERIMENTAL
Intervention: PaGES Index (before and after birth)
Number of subjects: 68
Study 37759174 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative evaluation (qMOLI)
Number of subjects: 68
Study 37759212 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised group-based walking intervention
Number of subjects: 0
Study 37759212 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-supervised individual-based walking intervention
Number of subjects: 0
Study 37759212 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37759268 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic platelet transfusion
Number of subjects: 181
Study 37759324 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized multimodal treatment (individualized physical exercise program combined with individualized nutritional therapy) for 12 weeks
Number of subjects: 0
Study 37759324 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy for 12 weeks
Number of subjects: 0
Study 37759330 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat-to-target (T2T)
Number of subjects: 284
Study 37759330 — intervention group
Group type: COMPARATOR
Intervention: Routine care (RC)
Number of subjects: 284
Study 37759489 — intervention group
Group type: EXPERIMENTAL
Intervention: PARPi-niraparib therapy
Number of subjects: 31
Study 37760514 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist and diabetologist interventions
Number of subjects: 102
Study 37760514 — intervention group
Group type: EXPERIMENTAL
Intervention: ONCODIAB follow-up
Number of subjects: 102
Study 37762777 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom questionnaire (65-item WISE symptom questionnaire)
Number of subjects: 916
Study 37764667 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral probiotic
Number of subjects: 0
Study 37764667 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 37764780 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-week telephone-based lifestyle intervention (n = 27)
Number of subjects: 40
Study 37764780 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 13)
Number of subjects: 40
Study 37764840 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole milk-based goat milk formula (GMF)
Number of subjects: 64
Study 37764840 — intervention group
Group type: COMPARATOR
Intervention: Whey-based cow milk formula (CMF)
Number of subjects: 64
Study 37765023 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone + Azathioprine
Number of subjects: 0
Study 37765023 — intervention group
Group type: COMPARATOR
Intervention: Romiplostim
Number of subjects: 0
Study 37765023 — intervention group
Group type: COMPARATOR
Intervention: High-dose Dexamethasone (HD-DXM)
Number of subjects: 0
Study 37765023 — intervention group
Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 0
Study 37765023 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag following HD-DXM
Number of subjects: 0
Study 37765154 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous levobupivacaine wound infiltration
Number of subjects: 120
Study 37765154 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus levobupivacaine wound infiltration
Number of subjects: 120
Study 37765154 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac analgesia
Number of subjects: 120
Study 37765154 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine PCA
Number of subjects: 120
Study 37766218 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-sensitive targeted PCR assay coupled with next-generation sequencing (NGS) for characterising HIV-1 DNA drug resistance mutations (DRMs).
Number of subjects: 0
Study 37766218 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-sensitive targeted PCR assay coupled with next-generation sequencing (NGS).
Number of subjects: 0
Study 37766505 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir-based ART (DTG)
Number of subjects: 229
Study 37766505 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care treatment (SOC)
Number of subjects: 229
Study 37766731 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release β-alanine (15 g/day divided into 3 intakes for 30 days)
Number of subjects: 19
Study 37766731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 37766731 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release β-alanine
Number of subjects: 19
Study 37766747 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature-based intervention (guided nature walks)
Number of subjects: 0
Study 37766747 — intervention group
Group type: COMPARATOR
Intervention: Exercise-based intervention (group exercise)
Number of subjects: 0
Study 37766882 — intervention group
Group type: EXPERIMENTAL
Intervention: Food insecurity intervention (specific details not provided)
Number of subjects: 0
Study 37766882 — intervention group
Group type: COMPARATOR
Intervention: Control group (specific details not provided)
Number of subjects: 0
Study 37766884 — intervention group
Group type: EXPERIMENTAL
Intervention: MediYoga (performed for one hour/week over a 12-week period)
Number of subjects: 0
Study 37766884 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study 37766922 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-free diet for 12 months
Number of subjects: 78
Study 37767191 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib maintenance treatment
Number of subjects: 49
Study 37767195 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat-to-target strategy with a target LDL-C level of 50-70 mg/dL
Number of subjects: 4400
Study 37767195 — intervention group
Group type: COMPARATOR
Intervention: High-intensity statin treatment
Number of subjects: 4400
Study 37767632 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated Shockwaves Lithotripsy
Number of subjects: 0
Study 37767632 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 37767674 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 6263
Study 37767674 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 6263
Study 37767674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6263
Study 37767823 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (BLT)
Number of subjects: 14
Study 37767823 — intervention group
Group type: COMPARATOR
Intervention: Sham bright light therapy
Number of subjects: 14
Study 37767993 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 1 (TSP-9 results provided)
Number of subjects: 259
Study 37767993 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 2 (option to order TSP-9 results)
Number of subjects: 259
Study 37767993 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TSP-9 results)
Number of subjects: 259
Study 37768018 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex chromosome dosage (SCD)
Number of subjects: 177
Study 37768018 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal measures from karyotypes (XXX, XXY, XYY, XXYY)
Number of subjects: 177
Study 37768273 — intervention group
Group type: EXPERIMENTAL
Intervention: Choriocapillaris flow signal deficits (FD%) in early AMD (N = 122)
Number of subjects: 410
Study 37768273 — intervention group
Group type: EXPERIMENTAL
Intervention: Choriocapillaris flow signal deficits (FD%) in intermediate AMD (N = 92)
Number of subjects: 410
Study 37768273 — intervention group
Group type: COMPARATOR
Intervention: Choriocapillaris flow signal deficits (FD%) in normal eyes (N = 196)
Number of subjects: 410
Study 37768273 — intervention group
Group type: EXPERIMENTAL
Intervention: Rod-mediated dark adaptation (RMDA)
Number of subjects: 410
Study 37768273 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast sensitivity
Number of subjects: 410
Study 37768273 — intervention group
Group type: EXPERIMENTAL
Intervention: Choriocapillaris FD% in eyes with subretinal drusenoid deposits (SDD) (N = 87)
Number of subjects: 410
Study 37768273 — intervention group
Group type: COMPARATOR
Intervention: Choriocapillaris FD% in eyes without subretinal drusenoid deposits (SDD) (N = 323)
Number of subjects: 410
Study 37768317 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rifampicin (40 mg/kg daily, RIF40)
Number of subjects: 25
Study 37768317 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose rifampicin (10 mg/kg daily, RIF10)
Number of subjects: 25
Study 37768344 — intervention group
Group type: COMPARATOR
Intervention: Aerobic Exercise (AE)
Number of subjects: 109
Study 37768344 — intervention group
Group type: COMPARATOR
Intervention: Combined Training (COMB)
Number of subjects: 109
Study 37768344 — intervention group
Group type: COMPARATOR
Intervention: Computerized Cognitive Training (CCT)
Number of subjects: 109
Study 37768427 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP disclosure and social support
Number of subjects: 451
Study 37768427 — intervention group
Group type: COMPARATOR
Intervention: PrEP use
Number of subjects: 451
Study 37768628 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted-Coping With Stress course (A-CWS)
Number of subjects: 410
Study 37768628 — intervention group
Group type: COMPARATOR
Intervention: Standard care control condition
Number of subjects: 410
Study 37768631 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week meditation app
Number of subjects: 0
Study 37768631 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 37768633 — intervention group
Group type: EXPERIMENTAL
Intervention: StriveWeekly web-based intervention
Number of subjects: 0
Study 37768658 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiragolumab (2 mg escalating to 1200 mg) in phase 1a and combination with Atezolizumab (1200 mg every 3 weeks) in phase 1b
Number of subjects: 73
Study 37768658 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Tiragolumab plus Atezolizumab
Number of subjects: 73
Study 37768658 — intervention group
Group type: COMPARATOR
Intervention: Tiragolumab alone
Number of subjects: 73
Study 37768670 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT plus lapatinib (1500 mg per day)
Number of subjects: 142
Study 37768670 — intervention group
Group type: COMPARATOR
Intervention: CRT plus placebo
Number of subjects: 142
Study 37768670 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT plus lapatinib
Number of subjects: 142
Study 37768671 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplontersen (45 mg every 4 weeks; n=144)
Number of subjects: 168
Study 37768671 — intervention group
Group type: COMPARATOR
Intervention: Placebo (historical control; n=60)
Number of subjects: 168
Study 37768713 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Brains (AB)
Number of subjects: 260
Study 37768713 — intervention group
Group type: COMPARATOR
Intervention: Health Enhancement Program (HEP)
Number of subjects: 260
Study 37768719 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional training group (lecture-based training)
Number of subjects: 29
Study 37768719 — intervention group
Group type: COMPARATOR
Intervention: VR-based training group (VR-based ALS serious game module)
Number of subjects: 29
Study 37768719 — intervention group
Group type: COMPARATOR
Intervention: Preference survey
Number of subjects: 29
Study 37768980 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy eating and stress management program
Number of subjects: 107
Study 37769113 — intervention group
Group type: EXPERIMENTAL
Intervention: Larotrectinib 100 mg orally twice daily
Number of subjects: 36
Study 37769182 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle Intervention
Number of subjects: 0
Study 37769182 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 37769181 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan/hydrochlorothiazide combination 150/12.5 mg once daily, with up-titration to 300/12.5 mg/day and 300/25 mg/day at 4 and 8 weeks, respectively.
Number of subjects: 215
Study 37769181 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan/hydrochlorothiazide combination treatment.
Number of subjects: 215
Study 37769187 — intervention group
Group type: EXPERIMENTAL
Intervention: Monofocal IOL implantation
Number of subjects: 29
Study 37769308 — intervention group
Group type: EXPERIMENTAL
Intervention: Occipital nerve block
Number of subjects: 62
Study 37769308 — intervention group
Group type: COMPARATOR
Intervention: Standard care (oral 650 mg acetaminophen and 200 mg caffeine)
Number of subjects: 62
Study 37769311 — intervention group
Group type: EXPERIMENTAL
Intervention: Elagolix 150 mg once daily
Number of subjects: 82
Study 37769311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 37769314 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean BP below 130/80 mm Hg
Number of subjects: 2096
Study 37769314 — intervention group
Group type: COMPARATOR
Intervention: Mean BP 130-139/80-89 mm Hg
Number of subjects: 2096
Study 37769319 — intervention group
Group type: COMPARATOR
Intervention: Quartile 1 (least disadvantaged)
Number of subjects: 8983
Study 37769319 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile 4 (most disadvantaged)
Number of subjects: 8983
Study 37769319 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile 2
Number of subjects: 8983
Study 37769319 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile 3
Number of subjects: 8983
Study 37769369 — intervention group
Group type: EXPERIMENTAL
Intervention: modified ketogenic diet (mKD)
Number of subjects: 20
Study 37769369 — intervention group
Group type: COMPARATOR
Intervention: placebo diet (PD)
Number of subjects: 20
Study 37769428 — intervention group
Group type: EXPERIMENTAL
Intervention: Inebilizumab 300 mg IV on Days 1 and 15
Number of subjects: 47